HOME >> MEDICINE >> NEWS
Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

(PHILADELPHIA) -- The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, the researchers say.

The team of scientists including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer 21 months.

Dr. Moreno presents the trials findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.

The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. If chemotherapy doesnt reduce the CTC level, its information that enables the physician to change the drug regimen or perhaps stop treatment, he says.

Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that th
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
4-Jun-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
Breaking Medicine Technology:
Cached News: